2021
DOI: 10.1111/bjh.17430
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Descriptions of passenger lymphocyte syndrome (PLS), immune cytopenias and transplant-associated thrombotic microangiopathy (TA-TMA) after intestine-containing transplants remain scarce. We describe our centre's experience of these complications from 2007 to 2019. Ninety-six patients received 103 transplants. PLS occurred in 9 (9%) patients (median 12 days post-transplant); all due to ABO antibodies. There were 31 minor ABO mismatch transplants. No patient required change in immunosuppression. Immune cytopenia… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 34 publications
0
4
0
Order By: Relevance
“…It is associated with a high degree of morbidity or mortality and can result in loss of the graft. The value of TPE following SOT remains controversial, but small CS are published (Thomas, 2021). Complement blockade with eculizumab is also utilized.…”
Section: Rationale For Therapeutic Apheresismentioning
confidence: 99%
“…It is associated with a high degree of morbidity or mortality and can result in loss of the graft. The value of TPE following SOT remains controversial, but small CS are published (Thomas, 2021). Complement blockade with eculizumab is also utilized.…”
Section: Rationale For Therapeutic Apheresismentioning
confidence: 99%
“…TPE has been reportedly used for the treatment of PLS. 6,[15][16][17] However, a lack of clear clinical guidelines has been observed regarding the end point of TPE for the treatment of PLS. Based on the ideas of the pathogenic mechanism of PLS, donor-derived lymphocytes produced antibodies against the recipient's RBCs, resulting in hemolysis.…”
Section: Discussionmentioning
confidence: 99%
“…We managed the patient with TPE to deplete the circulating anti‐A IgG antibodies. TPE has been reportedly used for the treatment of PLS 6,15–17 . However, a lack of clear clinical guidelines has been observed regarding the end point of TPE for the treatment of PLS.…”
Section: Discussionmentioning
confidence: 99%
“…1 Although infections and graft-versus-host disease (GVHD) have historically been the major contributors to transplant-related nonrelapse mortality, 2,3 transplant-associated thrombotic microangiopathy (TA-TMA) has increasingly become recognized as an independent entity with incidence rates of 8.2% to 39%. [4][5][6][7] It is characterized by the development of post-transplant hemolysis with schistocytes, thrombocytopenia, and organ dysfunction. Kidneys are the most common organs to become involved; intestinal involvement is also recognized.…”
Section: Introductionmentioning
confidence: 99%